NCT01658995View on ClinicalTrials.gov

Management of Etonogestrel Subdermal Implant-related Bleeding

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 13, 2012

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
ESI-related Bleeding
Interventions
DRUG

Doxycycline

Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.

DRUG

Placebo

Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Petra M. Casey

OTHER

NCT01658995 - Management of Etonogestrel Subdermal Implant-related Bleeding | Biotech Hunter | Biotech Hunter